Cargando…
Low skeletal muscle mass is predictive of dose-limiting toxicities in head and neck cancer patients undergoing low-dose weekly cisplatin chemoradiotherapy
BACKGROUND: The dose-limiting effect of CT-assessed low skeletal muscle mass (LSMM) measured at the level of the third cervical vertebra has been found in head and neck cancer patients receiving high-dose cisplatin chemoradiotherapy. The aim of this study was to investigate the predictive factors fo...
Autores principales: | Becker, Jan-Niklas, Hermann, Robert, Wichmann, Jörn, Sonnhoff, Mathias, Christiansen, Hans, Bruns, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942991/ https://www.ncbi.nlm.nih.gov/pubmed/36802403 http://dx.doi.org/10.1371/journal.pone.0282015 |
Ejemplares similares
-
Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol
por: Schaeffers, Anouk W. M. A., et al.
Publicado: (2023) -
Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma
por: Shinohara, Shogo, et al.
Publicado: (2021) -
The association of pretreatment low skeletal muscle mass with chemotherapy dose‐limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high‐dose cisplatin
por: Bril, Sandra I., et al.
Publicado: (2021) -
Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer
por: Szturz, Petr, et al.
Publicado: (2019) -
Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer
por: Wolff, Hendrik Andreas, et al.
Publicado: (2008)